Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

Stethoscope on a white puzzle piece with a written word ovarian cancer on a pink background

Related Content

Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor

Oct 12 2016

Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx

Oct 14 2016

<em>Lynparza</em> Approval Shows Benefit/Risk Contrast In Maintenance, Relapse Settings

Jan 05 2015

Related Companies

AstraZeneca PLC

Myriad Genetics, Inc.

Tesaro, Inc.

Clovis Oncology, Inc.

Additional Topics

Research & Development Companies Clinical Trials Cancer BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window